Related Experiment Video
Updated: Aug 12, 2026
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
An oxygen sensitive self-decision making engineered CAR T-cell
Alexandre Juillerat1, Alan Marechal2, Jean Marie Filhol2
1Cellectis Inc, 430E, 29th street, NYC, NY 10016, USA.
Abstract:
A key to the success of chimeric antigen receptor (CAR) T-cell based therapies greatly rely on the capacity to identify and target antigens with expression restrained to tumor cells. Here we present a strategy to generate CAR T-cells that are only effective locally (tumor tissue), potentially also increasing the choice of targetable antigens. By fusing an oxygen sensitive subdomain of HIF1α to a CAR scaffold, we generated CAR T-cells that are responsive to a hypoxic environment, a hallmark of certain tumors. Along with the development of oxygen-sensitive CAR T-cells, this work also provides a basic framework to use a multi-chain CAR as a platform to create the next generation of smarter self-decision making CAR T-cells.
Insights
Researchers developed novel oxygen-sensitive chimeric antigen receptor (CAR) T-cells. These CAR T-cells target tumors in hypoxic environments, enhancing cancer therapy safety and expanding antigen targeting options.
Area of Science:
- Immunotherapy
- Cancer Biology
- Molecular Engineering
Background:
- Chimeric antigen receptor (CAR) T-cell therapies show promise but require precise tumor-specific antigen targeting.
- Off-tumor toxicity and limited antigen selection remain significant challenges in CAR T-cell therapy development.
- Tumor microenvironments often exhibit hypoxia, a characteristic that can be exploited for targeted therapies.
Purpose of the Study:
- To engineer CAR T-cells with localized activity within the tumor microenvironment.
- To develop a hypoxia-responsive CAR T-cell system to enhance tumor specificity and safety.
- To establish a platform for next-generation, self-decision-making CAR T-cells.
Main Methods:
- Engineered CAR T-cells by fusing an oxygen-sensitive subdomain of Hypoxia-Inducible Factor 1-alpha (HIF1α) to a CAR scaffold.
- Developed a novel multi-chain CAR construct for enhanced functionality and responsiveness.
- Utilized hypoxic conditions as a trigger for CAR T-cell activation and tumor targeting.
Main Results:
- Successfully generated CAR T-cells that are specifically responsive to the hypoxic tumor microenvironment.
- Demonstrated a strategy for localized CAR T-cell efficacy, potentially reducing off-target effects.
- Established a foundational framework for creating advanced, adaptive CAR T-cell therapies.
Conclusions:
- Oxygen-sensitive CAR T-cells represent a promising approach to improve the safety and efficacy of T-cell based cancer immunotherapies.
- Exploiting tumor-specific conditions like hypoxia can broaden the scope of targetable antigens and enhance therapeutic precision.
- The developed multi-chain CAR platform facilitates the creation of sophisticated, self-regulating CAR T-cells for future cancer treatments.
